Search
Treatment and survival of patients with chronic myeloid leukemia (CML) in Europe
Since the introduction of tyrosine kinase inhibitors into the treatment of CML survival times have greatly improved.
Read moreUrgent action needed to avoid widespread shortage of in-vitro diagnostic tests
In a new statement, BioMed Alliance highlights its increasing concern about the availability of In Vitro Diagnostic (IVD) testing devices in Europe.
Read moreEHA attends the EuNet-INNOCHRON Final Conference
The EuNet-INNOCHRON Final Conference, a significant event in the field of hematology, took place in Chania, Crete, Greece from April 4-6, 2024.
Read moreEHA-EMN Joint Session at the European Myeloma Network Meeting EMN2023
On Saturday, 22 April, EHA and EMN brought together patients, regulators and clinicians to discuss Novel Endpoints in Multiple Myeloma.
Read moreDaratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study
Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.
Read morePromising results in trials with non-chemotherapy treatments for Leukemias to be presented at the 18th Congress of the European Hematology Association in Stockholm, June 13-16, 2013
What is new? Current investigations are aimed at evaluating the use of monoclonal antibodies (mAB). These mABs bind to specific molecules (antigens) found on leukemic cells. This results in immune destruction of the leukemic cells.
Read more